Combination of pharmacotherapy with electroconvulsive therapy in prevention of depressive relapse: a pilot controlled trial

The Journal of ECT
Ayşegül YildizHüray Fidaner

Abstract

Relapse rates after electroconvulsive therapy (ECT) remain high with standard treatments. We aimed to test the efficacy of an early administered continuation pharmacotherapy (c-pharm early) strategy in prevention of post-ECT relapse. A 20-week, randomized, double-blind, placebo-controlled trial. Patients aged 18 to 65 years diagnosed with Diagnostic and Statistical Manual of Mental Disorders major depressive disorder, with or without psychotic features, with initial Montgomery-Asberg Depression Rating Scale scores higher than 22, underwent 8 bilateral ECT sessions (2 per week). Randomization to c-pharm early, c-pharm late, and placebo groups in 2:2:1, respectively, was performed at the completion of the fourth ECT session. After randomization, subjects in the c-pharm early group were given sertraline at 150 mg/d. Subjects in the c-pharm late group were first given placebo, which was substituted with sertraline at 150 mg/d at the completion of the eight ECT. Relapse was defined as a Montgomery-Asberg Depression Rating Scale score of 16 or higher. Seventy-three percent of the patients responded to the given treatment. The relapse rates were 12.5% in the c-pharm early group, 28% in the c-pharm late group, and 67% in the placebo gr...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Feb 1, 1996·The American Journal of Psychiatry·S E Hyman, E J Nestler
Mar 14, 2001·Journal of Affective Disorders·M Fink
Mar 20, 2001·JAMA : the Journal of the American Medical Association·H A SackeimJ Prudic
Jun 28, 2001·JAMA : the Journal of the American Medical Association·R Abrams
Nov 27, 2001·British Medical Bulletin·V A Vaidya, R S Duman
Aug 16, 2002·Bipolar Disorders·Carrol D'Sa, Ronald S Duman
Mar 7, 2003·The Journal of ECT·J Calvin RussellTeresa A Rummans
Jan 28, 2004·Biological Psychiatry·Joan PrudicHarold A Sackeim
May 3, 2005·The American Journal of Psychiatry·Charles H KellnerChitra Malur
Nov 23, 2005·The Journal of ECT·Tom K BirkenhägerAriejan de Lely
Apr 25, 2007·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·James D TewHarold A Sackeim
Dec 7, 2007·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Sidney H Kennedy, Peter Giacobbe
Nov 19, 2008·The Journal of Clinical Psychiatry·Willemijn T C HeijnenTom K Birkenhäger

❮ Previous
Next ❯

Citations

Jun 19, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ana JelovacDeclan M McLoughlin
Dec 28, 2011·International Review of Psychiatry·Charlotte L Allan, Klaus P Ebmeier
Jul 15, 2015·The International Journal of Neuropsychopharmacology·Kang SimRoss J Baldessarini
Aug 26, 2011·The Journal of ECT·Defne EraslanOzgur Ozturk
Dec 20, 2017·The Australian and New Zealand Journal of Psychiatry·Alby EliasJoan Prudic
Dec 23, 2016·The International Journal of Neuropsychopharmacology·Ross J BaldessariniKang Sim

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.